Remington-Davis’ extensive experience allows us to consistently surpass study start-up timelines and vaccine study enrollment goals. We ensure high-quality data and deliver engaged patients in both government and industry-sponsored clinical trials. We have completed over 600 clinical trials since 1992. A few examples of our experience include:

• Three separate C. difficile vaccine studies, wherein an average of 50 subjects were randomized per study
• Seasonal influenza vaccine study; rapid study start-up and enrollment mattered
• Two government anti-botulism vaccine studies, with an average of 21 enrolled healthy adult volunteers per study
• Staph aureus vaccine study with 52 randomized subjects
• Norovirus vaccine study; 120 subjects randomized in eight weeks with only six screen failures; our excellent performance led to our selection for a third- cohort when additional patients were needed

Institutional Biosafety Committee (IBC)

Advarra IRB serves as Remington-Davis’s Institutional Biosafety Committee (IBC). Our IBC approval is active. In accordance with NIH transparency requirements, approved IBC meeting minutes are publicly available here.

Recently remodeled, the facility has added the capability to sleep up to four patients per night. Each private room is equipped with a desk, bed, recliner, end table, and television. An on-site kitchen where meals are prepared, or brought in, and a full bathroom with handicapped accessible shower are steps away from each patient room.

Staff is a combination of licensed and certified full-time study coordinators and nurses, supported by a dedicated regulatory department, quality assurance department, and patient recruiter. The management team has over 100 years of combined research experience.